<!DOCTYPE html><html><head><title>Chronic graft versus host disease (cGVHD): percentage of patients with cGVHD who were prescribed pneumococcal prophylaxis.</title><link rel="stylesheet" type="text/css" href="style.css"></head><body><div class='section'>
<h2>General
</h2>
<div class='field field_text'>
<h3>
Title
</h3>
<div class='FieldValue'>
<div class="content_title">Chronic graft versus host disease (cGVHD): percentage of patients with cGVHD who were prescribed pneumococcal prophylaxis.</div>
</div>

</div>
<div class='field field_citation'>
<h3>
Source(s)
</h3>
<div class='FieldValue'>
<table><tr><td>Proposed chronic graft versus host disease measure set: questionnaire, measures with specifications, glossary. Arlington Heights (IL): American Society for Blood and Marrow Transplantation; 26 p. </td></tr></table>
</div>

</div>

</div>
<div class='section'>
<h2>Measure Domain
</h2>
<div class='field field_picklist-one'>
<h3>
Primary Measure Domain
</h3>
<div class='FieldValue'>
Clinical Quality Measures: Process
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Secondary Measure Domain
</h3>
<div class='FieldValue'>
Does not apply to this measure
</div>

</div>

</div>
<div class='section'>
<h2>Brief Abstract
</h2>
<div class='field field_text'>
<h3>
Description
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This measure is used to assess the percentage of patients with chronic graft versus host disease (cGVHD) who were prescribed pneumococcal prophylaxis.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Rationale
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The pathogenesis of chronic graft versus host disease (cGVHD) is poorly understood. Symptoms usually present within 3 years after allogeneic hematopoietic cell transplantation (HCT) and are often preceded by a history of acute GVHD. Manifestations of chronic GVHD may be restricted to a single organ or tissue or may be widespread. Chronic GVHD can lead to debilitating consequences, e.g., joint contractures, loss of sight, end-stage lung disease, or mortality resulting from profound chronic immune suppression leading to recurrent or life-threatening infections. </p>
<p><em>Support (verbatim) from National Institutes of Health (NIH) Consensus Development Project</em>: Antibiotic prophylaxis against pneumococcal infection is indicated in patients with chronic graft versus host disease (cGVHD) and those with low immunoglobulin G (IgG) levels. Antibiotic prophylaxis should be administered even to patients who have received pneumococcal vaccine, because not all strains are included in the vaccines, the immunogenicity of vaccines against the vaccine strains in hematopoietic cell transplantation (HCT) patients is only, at most, about 80%, and because of the theoretic concern that strains not included in the vaccine will replace vaccine strains. Oral penicillin remains the preferred choice, but antibiotic selection depends on the local pattern of pneumococcal resistance to penicillin and other antibiotics (i.e., second-generation cephalosporins, macrolides, and quinolones). </p>
<p><em>Statements (verbatim) on gap</em>: Invasive pneumococcal infection (IPI) is a life threatening complication that may occur months to years after HCT. The annual incidence of IPI is 8.23/1000 transplants among allogeneic HCT recipients, and higher still among those with cGVHD (20.8/1000 transplants). Although IPI occurs less frequently in autologous HCT recipients (annual incidence, 3.8/1000 transplants), the risk remains much higher than in an immunocompetent population. </p></div>
</div>

</div>
<div class='field field_citation'>
<h3>
Evidence for Rationale
</h3>
<div class='FieldValue'>
<table><tr><td>Cordonnier C, Labopin MV, et al. Influence of immunisation timing on the response to conjugate-pneumococcal vaccine after allogeneic stem cell transplant: final results of the EBMT IDWP01 Trial. Bone Marrow Transplant. 2008;45</td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Engelhard D, Cordonnier C, Shaw PJ, Parkalli T, Guenther C, Martino R, Dekker AW, Prentice HG, Gustavsson A, Nurnberger W, Ljungman P, Infectious Disease Working Party of the European Bone Marrow Transplantation. Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. Br J Haematol. 2002 May;117(2):444-50. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11972532" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16338616" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Haddad PA, Repka TL, Weisdorf DJ. Penicillin-resistant Streptococcus pneumoniae septic shock and meningitis complicating chronic graft versus host disease: a case report and review of the literature. Am J Med. 2002 Aug 1;113(2):152-5. [34 references] <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12133754" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Jenkins SG, Brown SD, Farrell DJ. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4. Ann Clin Microbiol Antimicrob. 2008;7:1. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=18190701" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Patel SR, Ortin M, Cohen BJ, Borrow R, Irving D, Sheldon J, Heath PT. Revaccination with measles, tetanus, poliovirus, Haemophilus influenzae type B, meningococcus C, and pneumococcus vaccines in children after hematopoietic stem cell transplantation. Clin Infect Dis. 2007 Mar 1;44(5):625-34. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=17278051" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Perez Retortillo JA, Marco F, Richard C, Conde E, Manjon R, Bureo E, Iriondo A, Zubizarreta A. Pneumococcal pericarditis with cardiac tamponade in a patient with chronic graft-versus-host disease. Bone Marrow Transplant. 1998 Feb;21(3):299-300. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9489655" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Proposed chronic graft versus host disease measure set: questionnaire, measures with specifications, glossary. Arlington Heights (IL): American Society for Blood and Marrow Transplantation; 26 p. </td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Sullivan KM. Graft vs. host disease. In: Blume KG, Forman SJ, Appelbaum FR, editor(s). Thomas' Hematopoietic Cell Transplantation. 3rd ed. Malden (MA): Blackwell Publishing; 2004. p. 635-64.</td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Tauro S, Dobie D, Richardson G, Hastings M, Mahendra P. Recurrent penicillin-resistant pneumococcal sepsis after matched unrelated donor  (MUD) transplantation for refractory T cell lymphoma. Bone Marrow Transplant. 2000 Nov;26(9):1017-9. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11100283" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Wingard JR, Young JA, Boeckh MJ, Center for International Blood and Marrow Research, National Marrow Donor program, European Blood and Marrow Transplant Group, American Society of Blood and Marrow Transplantation, Canadian Blood and Marrow Transplant Group, Infectious Diseases Society of America, Society for Healthcare Epidemiology of America, Association of Medical Microbiology and Infectious Disease Canada, Centers for Disease Control and Prevention. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009 Oct;15(10):1143-238. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=19747629" target="_blank">PubMed</a></td></tr></table>
</div>

</div>
<div class='field field_text'>
<h3>
Primary Health Components
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Chronic graft versus host disease (cGVHD); pneumococcal prophylaxis</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Denominator Description
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The number of patients in your selection diagnosed with chronic graft versus host disease (cGVHD) (see the related "Denominator Inclusions/Exclusions" field) </p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Numerator Description
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The number of patients in your selection diagnosed with chronic graft versus host disease (cGVHD) AND were prescribed pneumococcal prophylaxis (see the related "Numerator Inclusions/Exclusions" field)</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Evidence Supporting the Measure
</h2>
<div class='field field_picklist-choice'>
<h3>
Type of Evidence Supporting the Criterion of Quality for the Measure
</h3>
<div class='FieldValue'>
A clinical practice guideline or other peer-reviewed synthesis of the clinical research evidence
</div>
<div class='FieldValue'>
A formal consensus procedure, involving experts in relevant clinical, methodological,  public health and organizational sciences
</div>
<div class='FieldValue'>
One or more research studies published in a National Library of Medicine (NLM) indexed, peer-reviewed journal
</div>

</div>
<div class='field field_text'>
<h3>
Additional Information Supporting Need for the Measure
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Reported incidence rates of chronic graft versus host disease (cGVHD) after allogeneic transplantation range from 6% to 80% according to recipient age, donor type, hematopoietic cell transplantation (HCT) source (peripheral blood, bone marrow, or umbilical cord blood stem cells), graft manipulation (T-cell depletion), and use of post transplantation donor lymphocyte infusion (DLIs). Reliable incidence estimates in different cohorts of HCT recipients are compromised by (1) lack of standardized, widely used diagnostic guidelines; (2) variability in observer experience; (3) limited expert follow-up at a distance from transplant centers; (4) differences in the statistical methods applied (e.g., use of the Kaplan-Meier versus cumulative incidence estimates and variable requirement for some minimal survival [60-100 days] for patients to be considered at risk of chronic GVHD); and (5) the sometimes protean nature of early chronic GVHD symptoms, which mimic alternative diagnoses.</p></div>
</div>

</div>
<div class='field field_citation'>
<h3>
Evidence for Additional Information Supporting Need for the Measure
</h3>
<div class='FieldValue'>
<table><tr><td>Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16338616" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Remberger M, Aschan J, Lonnqvist B, Carlens S, Gustafsson B, Hentschke P, Klaesson S, Mattsson J, Ljungman P, Ringden O. An ethnic role for chronic, but not acute, graft-versus-host disease after HLA-identical sibling stem cell transplantation. Eur J Haematol. 2001 Jan;66(1):50-6. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11168508" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Rocha V, Wagner JE Jr, Sobocinski KA, Klein JP, Zhang MJ, Horowitz MM, Gluckman E. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone  Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med. 2000 Jun 22;342(25):1846-54. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10861319" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, Erickson K, Flowers M, Hansen J, Loughran T, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991 Jul;28(3):250-9. [75 references] <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=1887253" target="_blank">PubMed</a></td></tr></table>
</div>

</div>
<div class='field field_text'>
<h3>
Extent of Measure Testing
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The Chronic Graft Versus Host Disease (cGVHD) measure set was developed by the American Society for Blood and Marrow Transplantation (ASBMT) using a rigorous methodology (adapted from the American Medical Association's Physician Consortium for Performance Improvement [AMA-PCPI] and including field testing) and adapted for use in Practice Improvement Modules (PIMs) by the American Board of Internal Medicine (ABIM).</p></div>
</div>

</div>
<div class='field field_citation'>
<h3>
Evidence for Extent of Measure Testing
</h3>
<div class='FieldValue'>
<table><tr><td>Joseph TL. (Executive Director, American Society for Blood and Marrow Transplantation). Personal communication. 2013 Jan 21. &nbsp;1 p. </td></tr></table>
</div>

</div>

</div>
<div class='section'>
<h2>State of Use of the Measure
</h2>
<div class='field field_picklist-one'>
<h3>
State of Use
</h3>
<div class='FieldValue'>
Current routine use
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Current Use
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>

</div>
<div class='section'>
<h2>Application of the Measure in its Current Use
</h2>
<div class='field field_picklist-choice'>
<h3>
Measurement Setting
</h3>
<div class='FieldValue'>
Ambulatory/Office-based Care
</div>
<div class='FieldValue'>
Hospital Inpatient
</div>
<div class='FieldValue'>
Hospital Outpatient
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Professionals Involved in Delivery of Health Services
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Least Aggregated Level of Services Delivery Addressed
</h3>
<div class='FieldValue'>
Clinical Practice or Public Health Sites
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Statement of Acceptable Minimum Sample Size
</h3>
<div class='FieldValue'>
Specified
</div>

</div>
<div class='field field_text'>
<h3>
Target Population Age
</h3>
<div class='FieldValue'>
<div class="content_para"><p>All ages</p></div>
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Target Population Gender
</h3>
<div class='FieldValue'>
Either male or female
</div>

</div>

</div>
<div class='section'>
<h2>National Strategy for Quality Improvement in Health Care
</h2>
<div class='field field_text'>
<h3>
National Quality Strategy Aim
</h3>
<div class='FieldValue'>
<ul><li>Better Care</li></ul>
</div>

</div>
<div class='field field_text'>
<h3>
National Quality Strategy Priority
</h3>
<div class='FieldValue'>
<ul><li>Making Care Safer</li><li>Prevention and Treatment of Leading Causes of Mortality</li></ul>
</div>

</div>

</div>
<div class='section'>
<h2>Institute of Medicine (IOM) National Health Care Quality Report Categories
</h2>
<div class='field field_picklist-choice'>
<h3>
IOM Care Need
</h3>
<div class='FieldValue'>
Living with Illness
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
IOM Domain
</h3>
<div class='FieldValue'>
Effectiveness
</div>
<div class='FieldValue'>
Safety
</div>

</div>

</div>
<div class='section'>
<h2>Data Collection for the Measure
</h2>
<div class='field field_text'>
<h3>
Case Finding Period
</h3>
<div class='FieldValue'>
<div class="content_para"><p>12 months</p></div>
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Denominator Sampling Frame
</h3>
<div class='FieldValue'>
Patients associated with provider
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Denominator (Index) Event or Characteristic
</h3>
<div class='FieldValue'>
Clinical Condition
</div>
<div class='FieldValue'>
Encounter
</div>
<div class='FieldValue'>
Therapeutic Intervention
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Denominator Time Window
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>
<div class='field field_text'>
<h3>
Denominator Inclusions/Exclusions
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong>Inclusions</strong> <br />
The number of patients in your selection diagnosed with chronic graft versus host disease (cGVHD) </p>
<p class="Note"><strong>Note</strong>: Patients can be included in the chart abstraction if:</p>
<ul class="Note" style="list-style-type: disc;">
    <li>They have been seen by the practice within the past 12 months; and </li>
    <li>Management decisions regarding care are made primarily by providers in the practice. </li>
</ul>
<p class="Note">Select at least 10 of your patients who have had hematopoietic cell transplant (HCT) and cGVHD. Refer to the original measure documentation for administrative codes.</p>
<p><strong>Exclusions </strong><br />
None </p></div>
</div>

</div>
<div class='field field_picklist-choice-4'>
<h3>
Exclusions/Exceptions
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>
<div class='field field_text'>
<h3>
Numerator Inclusions/Exclusions
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong>Inclusions </strong><br />
The number of patients in your selection diagnosed with chronic graft versus host disease (cGVHD) AND were prescribed pneumococcal prophylaxis </p>
<p class="Note"><strong>Note</strong>: This requires documentation in the patient's medical record that the patient was prescribed pneumococcal prophylaxis.</p>
<p><strong>Exclusions</strong> <br />
None</p></div>
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Numerator Search Strategy
</h3>
<div class='FieldValue'>
Fixed time period or point in time
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Data Source
</h3>
<div class='FieldValue'>
Administrative clinical data
</div>
<div class='FieldValue'>
Paper medical record
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Type of Health State
</h3>
<div class='FieldValue'>
Does not apply to this measure
</div>

</div>
<div class='field field_text'>
<h3>
Instruments Used and/or Associated with the Measure
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Computation of the Measure
</h2>
<div class='field field_picklist-one'>
<h3>
Measure Specifies Disaggregation
</h3>
<div class='FieldValue'>
Does not apply to this measure
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Scoring
</h3>
<div class='FieldValue'>
Rate/Proportion
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Interpretation of Score
</h3>
<div class='FieldValue'>
Desired value is a higher score
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Allowance for Patient or Population Factors
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Standard of Comparison
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>

</div>
<div class='section'>
<h2>Identifying Information
</h2>
<div class='field field_text'>
<h3>
Original Title
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Patients with chronic GVHD who were prescribed pneumococcal prophylaxis.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Measure Collection Name
</h3>
<div class='FieldValue'>
Chronic Graft Versus Host Disease Measure Set
</div>

</div>
<div class='field field_orglist'>
<h3>
Submitter
</h3>
<div class='FieldValue'>
American Society for Blood and Marrow Transplantation - Professional Association
</div>

</div>
<div class='field field_orglist-p'>
<h3>
Developer
</h3>
<div class='FieldValue'>
American Society for Blood and Marrow Transplantation - Professional Association
</div>

</div>
<div class='field field_text'>
<h3>
Funding Source(s)
</h3>
<div class='FieldValue'>
<div class="content_para"><p>American Society for Blood and Marrow Transplantation</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Composition of the Group that Developed the Measure
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The American Society for Blood and Marrow Transplantation (ASBMT) Education Practice Improvement Modules Task Force:</p>
<ul style="list-style-type: disc;">
    <li>Linda Burns, MD (<em>chair</em>) </li>
    <li>Stephan A Grupp, MD, PhD </li>
    <li>Mark B Juckett, MD </li>
    <li>Vivek Roy, MD </li>
    <li>Edward Agura, MD </li>
    <li>Miguel-Angel Perales, MD </li>
    <li>Thomas Joseph, MPS, CAE, ASBMT Executive Director </li>
    <li>Sue Frechette, BSN, MBA Consultant </li>
</ul></div>
</div>

</div>
<div class='field field_text'>
<h3>
Financial Disclosures/Other Potential Conflicts of Interest
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Conflicts, if any, are disclosed in accordance with the American Society for Blood and Marrow Transplantation (ASBMT) conflict of interest policy.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Adaptation
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This measure was not adapted from another source.</p></div>
</div>

</div>
<div class='field field_date'>
<h3>
Date of Most Current Version in NQMC
</h3>
<div class='FieldValue'>
2012 Apr
</div>

</div>
<div class='field field_text'>
<h3>
Measure Maintenance
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Date of Next Anticipated Revision
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Measure Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This is the current release of the measure.</p>
<p>The measure developer reaffirmed the currency of this measure in February 2017. </p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Measure Availability
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Source not available electronically.</p>
<p>For more information, contact the American Society for Blood and Marrow Transplantation (ASBMT) at 85 W. Algonquin Road, Suite 550, Arlington Heights, IL 60005; Phone: 847-427-0224; Fax: 847-427-9656; Web site: <a href="http://www.asbmt.org" title="ASBMT Web site">www.asbmt.org</a>; E-mail: <a href="mailto:mail@asbmt.org">mail@asbmt.org</a>.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
NQMC Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This NQMC summary was completed by ECRI Institute on September 24, 2013. The information was verified by the measure developer on October 25, 2013.</p>
<p>The information was reaffirmed by the measure developer on February 8, 2017. </p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Copyright Statement
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This NQMC summary is based on the original measure, which is subject to the measure developer's copyright restrictions.</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Production
</h2>
<div class='field field_citation'>
<h3>
Source(s)
</h3>
<div class='FieldValue'>
<table><tr><td>Proposed chronic graft versus host disease measure set: questionnaire, measures with specifications, glossary. Arlington Heights (IL): American Society for Blood and Marrow Transplantation; 26 p. </td></tr></table>
</div>

</div>

</div>
<div class='section'>
<h2>Disclaimer
</h2>
<div class='field field_text'>
<h3>
NQMC Disclaimer
</h3>
<div class='FieldValue'>
<p>The National Quality Measures Clearinghouseâ„¢ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.</p> 
<p>All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.</p> 
<p>Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the <a href="/help-and-about/summaries/inclusion-criteria">NQMC Inclusion Criteria</a>.</p> 
<p>NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding measure content are directed to contact the measure developer.</p>
</div>

</div>

</div>
</body></html>